Pharma Major Lupin announced that it has received final approval for its Metronidazole Tablets USP, 250 mg and 500 mg from the United States Food and Drug Administration (FDA) to market a generic version of G.D. Searle LLC's Flagyl Tablets, 250 mg and 500 mg.

Lupin's Metronidazole Tablets USP, 250 mg and 500 mg are the AB rated generic equivalent of G.D. Searle LLC's Flagyl Tablets, 250 mg and 500 mg. It is indicated in the treatment of wide variety of infections which are caused by particular types of bacteria and other infectious organisms.

Flagyl Tablets had US sales of USD 44.1 million (IMS MAT June 2017).

Shares of the company gained Rs 19.45, or 1.96%, to trade at Rs 1,011.55. The total volume of shares traded was 137,277 at the BSE (10.19 a.m., Thursday).